Q3 2025 Earnings Call Transcript November 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07. Operator: Greetings, and welcome to the Vaxart Business ...

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...

Vaxart secures major Dynavax deal, extending cash runway to 2027. Get Q3 earnings insights, clinical progress, and outlook on innovative oral vaccines.

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds ...

Norovirus triggers symptoms such as vomiting and diarrhoea. While it can be extremely unpleasant, it typically resolves ...

Finally! A microbiologist settles the debate on whether you need to keep the toilet lid down when you're not on the pot.

Louisville Metro Health and Wellness report public health researchers have detected an increase in norovirus levels in ...

Six people have died due to a multistate outbreak of listeria linked to recalled prepared pasta meals sold at major grocery ...

Portions of Broad Bay in Virginia Beach are closed to shellfish harvesting due to water contamination, the Virginia ...

Early diagnosis of reactive infectious mucocutaneous eruption is important to minimize potential long-term disease ...

The median concentration across all sites in October 2025 was 17.1k copies/gram (cp/g), a decrease of ~74% compared to ...